Enovis (Enovis) EBIT per Share : $-0.87 (TTM As of Dec. 2023)

View and export this data going back to 2008. Start your Free Trial

What is Enovis EBIT per Share?

Enovis's EBIT per Share for the three months ended in Dec. 2023 was $0.22. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.87.

During the past 3 years, the average EBIT per Share Growth Rate was 6.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Enovis's EBIT per Share or its related term are showing as below:

ENOV' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -38.3 Med: 2.65 Max: 315.3
Current: 6.4

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Enovis was 315.30% per year. The lowest was -38.30% per year. And the median was 2.65% per year.

ENOV's 3-Year EBIT Growth Rate is ranked worse than
54.15% of 2410 companies
in the Industrial Products industry
Industry Median: 9.4 vs ENOV: 6.40

Enovis's EBIT for the three months ended in Dec. 2023 was $12 Mil.

Enovis EBIT per Share Historical Data

The historical data trend for Enovis's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enovis EBIT per Share Chart

Enovis Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

3.73

-1.45

-1.81

0.41

-0.87

Enovis Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT per Share	Get a 7-Day Free Trial															0.07	-0.45	-0.28	-0.36	0.22

Enovis EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Enovis's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-47.379	/	54.495
=	-0.87

Enovis's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	11.91	/	54.592
=	0.22

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.87

Enovis (NYSE:ENOV) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Enovis EBIT per Share Related Terms

Thank you for viewing the detailed overview of Enovis's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Enovis (Enovis) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Industrials » Industrial Products » Enovis Corp (NYSE:ENOV) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

C520:Germany

Address

2711 Centerville Road, Suite 400, Wilmington, DE, USA, 19808

Website

https://www.enovis.com

Enovis Corp is a medical technology company focused on developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows by manufacturing and distributing high-quality medical devices with a broad range of products used for reconstructive surgery, rehabilitation, pain management and physical therapy.. The company conducts its operations through two operating segments: Prevention & Recovery ("P&R") and Reconstructive ("Recon"). It generates majority revenue form Prevention & Recovery segment.

Executives

John Kleckner	officer: Principal Accounting Officer	2711 CENTERVILLE ROAD, SUITE 400, WILMINGTON DE 19808
Berry Phillip Benjamin (ben)	officer: SVP, Chief Financial Officer	2711 CENTERVILLE ROAD SUITE 400, WILMINGTON DE 19808
Rajiv Vinnakota	director	8730 STONY POINT PARKWAY, SUITE 150, RICHMOND VA 23235
A Clayton Perfall	director
Brady Shirley	officer: EVP, Colfax, Pres. & CEO, DJO	2711 CENTERVILLE ROAD, SUITE 400, WILMINGTON DE 19808
Patricia A Lang	officer: SVP, Chief HR Officer	C/O DIEBOLD NIXDORF, INCORPORATED, 5995 MAYFAIR ROAD, NORTH CANTON OH 44720
Bradley J Tandy	officer: SVP, General Counsel	P.O. BOX 587, 56 E. BELL DRIVE, WARSAW IN 46580
Daniel A Pryor	officer: SVP??Strategy & Business Deve.	DANAHER CORP, 2099 PENNSYLVANIA AVE NW 12TH FL, WASHINGTON DC 20006
Matthew L. Trerotola	director, officer: President & CEO	2711 CENTERVILLE ROAD, SUITE 400, WILMINGTON DE 19808
Christopher M Hix	officer: SVP, Chief Financial Officer	2160 SATELLITE BLVD., SUITE 200, DULUTH GA 30097
Barbara W. Bodem	director	C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Christine Ortiz	director	1200 ABERNATHY ROAD, NE, SUITE 1200, ATLANTA GA 30328
Angela S Lalor	director	3M CENTER, BLDG. 0220-09-E-02, ST PAUL MN 55144 1000
Shyam Kambeyanda	officer: ESAB President and SVP, Colfax	2711 CENTERVILLE ROAD, SUITE 400, WILMINGTON DE 19808
Douglas J. Pitts	officer: Controller, PAO	100 MATSONFORD ROAD, RADNOR PA 19087